An Inclusive Litany

10/12/92

Levamisole, a drug that has been used in the past to combat intestinal parasites in farm animals has been approved for human use in combatting colon cancer. Still, to keep a sheep free from worms for a year costs $14.95, but a year's supply for human patients runs about $1,500.

Frank Glickman, who wanted the drug to aid his own recovery, has filed a class-action suit against Johnson & Johnson, the drug's maker. Johnson & Johnson says that the increased price was due to the research and development required to find an effective human use for the drug. However, Dr. Charles Moertel, who directed the effort to win FDA approval for the drug under the assurance from Johnson & Johnson that the drug would be reasonably priced, says the company didn't contribute any funds, and that the $10.6 million was covered by the National Cancer Institute, out of taxpayer's pockets. Furthermore, the veterinary and human versions of Levamisole are "exactly, absolutely identical." Glickman's attorney adds that a price breakdown for the drug by Johnson & Johnson shows that the major element in the price increase was promotion costs. "This for a drug that has no need to be promoted," he says. "It is the standard treatment for colon cancer, and it would be sheer lunacy for someone with the disease not to use it."